Equillium Inc EQ:NASDAQ

Last Price$2.47Cboe Real-Time Last Sale as of 11:59AM ET 5/20/22
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change-0.06(2.37%)
Bid (Size)$2.44 (100)
Ask (Size)$2.56 (100)
Day Low / High$2.47 - 2.60
Volume18.3 K

View Biotechnology IndustryPeer Comparison as of 05/20/2022


Equillium Inc ( NASDAQ )

Price: $2.47
Change: -0.06 (2.37%)
Volume: 18.3 K
11:59AM ET 5/20/2022

Epizyme Inc ( NASDAQ )

Price: $0.50
Change: -0.02 (4.15%)
Volume: 963.0 K
3:29PM ET 5/20/2022

Harpoon Therapeutics Inc ( NASDAQ )

Price: $2.47
Change: -0.16 (6.08%)
Volume: 194.1 K
2:54PM ET 5/20/2022

Magenta Therapeutics Inc ( NASDAQ )

Price: $1.20
Change: -0.26 (17.81%)
Volume: 451.6 K
3:02PM ET 5/20/2022

Entasis Therapeutics Holdings Inc ( NASDAQ )

Price: $1.79
Change: -0.04 (2.19%)
Volume: 42.9 K
1:22PM ET 5/20/2022

Read more news Recent News

-- Earnings Flash (EQ) EQUILLIUM Reports Q1 Loss $-1.17
4:03PM ET 5/12/2022 MT Newswires


HC Wainwright Adjusts Equillium's Price Target to $15 From $12, Reiterates Buy Rating
7:36AM ET 3/24/2022 MT Newswires

Equillium (EQ) has an average rating of buy and price targets ranging from $12 to $15, according to analysts polled by Capital IQ. (MT Newswires covers...

-- Earnings Flash (EQ) EQUILLIUM Reports Q4 Loss $-0.36
4:03PM ET 3/23/2022 MT Newswires


Equillium Starts Phase 3 Study of Itolizumab for Treatment of Acute Graft-Versus-Host Disease
8:28AM ET 3/04/2022 MT Newswires

Equillium (EQ) said Friday it has launched a phase 3 trial of itolizumab in patients with acute graft-versus-host disease, a multi-system disorder caused...

View all Commentary and Analysis

Equillium (EQ) Investor Presentation - Slideshow
2:50PM ET 12/13/2021 Seeking Alpha

Equillium CEO Bruce Steel - Drugs For Autoimmune, Inflammatory Disorders (Video)
11:30AM ET 10/08/2021 Seeking Alpha

Company Profile

Business DescriptionEquillium, Inc. engages in the development of products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. Its product pipeline includes EQ001, which is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly on March, 2017 and is headquartered in La Jolla, CA. View company web site for more details
Address2223 Avenida de la Playa
La Jolla, California 92037
Number of Employees11
Recent SEC Filing05/12/20228-K
President, Chief Executive Officer & DirectorBruce D. Steel
Chief Operating Officer & Senior Vice PresidentChristine Zedelmayer
Chief Financial OfficerJason A. Keyes
Director & Chief Scientific OfficerStephen Connelly

Company Highlights

Price Open$2.58
Previous Close$2.53
52 Week Range$2.12 - 7.75
Market Capitalization$84.7 M
Shares Outstanding34.3 M
SectorHealth Technology
Next Earnings Announcement08/09/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.36
Beta vs. S&P 500N/A
Net Profit MarginN/A
Return on Equity-48.97%

Analyst Ratings as of 05/13/2022

Consensus RecommendationConsensus Icon
Powered by Factset